药物诱发髂腰臀肌自发性出血1例分析

doi:10.19803/j.1672-8629.20220460

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (11): 1299-1302.
DOI: 10.19803/j.1672-8629.20220460

药物诱发髂腰臀肌自发性出血1例分析

谢婧, 关飞^*

重庆市东南医院药学部,重庆 400000

收稿日期:2022-08-03 出版日期:2023-11-15 发布日期:2023-11-13
通讯作者: ^*关飞,女,本科,主管药师,药事管理。E-mail：349053193@qq.com
作者简介:谢婧,女,本科,主管药师,临床药学。

One case of spontaneous hemorrhage of iliopsoas and gluteal muscles induced by drugss

XIE Jing, GUAN Fei^*

Department of Pharmacy, Chongqing Southeast Hospital, Chongqing 400000, China

Received:2022-08-03 Online:2023-11-15 Published:2023-11-13

摘要/Abstract

摘要： 目的分析那屈肝素、头孢哌酮舒巴坦、阿司匹林致髂腰臀肌出血治疗过程,为临床提供治疗参考。方法对1例联合使用那屈肝素、头孢哌酮舒巴坦、阿司匹林治疗出现自发性髂腰臀肌出血的患者诊疗过程进行回顾性分析。结果患者经保守治疗后,髂腰臀肌出血好转,但腰大肌血肿形成,转上级医院治疗。结论那屈肝素联合头孢哌酮舒巴坦、阿司匹林治疗可诱发罕见的深层肌肉出血,临床需警惕。

关键词: 那屈肝素, 头孢哌酮舒巴坦, 阿司匹林, 髂腰肌出血, 药品不良反应, 药物相互作用

Abstract: Objective To review the process of treating one case of the iliopsoas and gluteal muscle hemorrhage caused by nadroparin,aspirin, efoperazone sodium and sulbactam sodium for injection so as to provide reference for clinical treatment. Methods The diagnosis and treatment of a patient with spontaneous iliopsoas and gluteal muscle hemorrhage and treated with the combination of nadroparin, aspirin, cefoperazone sodium and sulbactam sodium for injection was retrospectively analyzed. Results After conventional treatment, the hemorrhage of the iliopsoas and gluteal muscle improved, but hematoma was formed in psoas muscles. Conclusion Treatment with nadroparin, aspirin, cefoperazone sodium and sulbactam sodium for injection can possibly induce a rare deep muscle hemorrhage, which deserves attention clinically.

Key words: nadroparin, cefoperazone/sulbactam, aspirin, iliopsoas muscle hemorrhage, adverse drug reaction, drug interaction

中图分类号:

R972
R994.11

谢婧, 关飞. 药物诱发髂腰臀肌自发性出血1例分析[J]. 中国药物警戒, 2023, 20(11): 1299-1302.

XIE Jing, GUAN Fei. One case of spontaneous hemorrhage of iliopsoas and gluteal muscles induced by drugss[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1299-1302.

参考文献

[1] XU L, ZHANG WX, XU BM, et al.Opinions of pharmaceutical experts on clinical application of nadroparin[J]. Shanghai Medical & Pharmaceutical Journal(上海医药), 2022, 43(21): 6.
[2] Dingxiangyuan. Nodroparin: Drug monograph(Topic1006 Version220.0) [EB/OL]. [2023-02-06]. https://www.uptodate.com/contents/zh-Hans/94072?kp_tab=drug_dxy&display_rank=1&search=nodroparin selected Title=1~25&source=panel_search_result.
[3] AGNELLI G, DEL FAVERO A, PARISE P, et al.Cephalosporin-induced hypoprothrombin- -emia: Is the N-methylthiotetrazole side chain the culprit?[J]. Antimicrob Agents Chemother, 1986, 29(6): 1108-1109.
[4] SCHENTAG JJ, WELAGE LS, WILLIAMS JS, et al.Kinetics and action of N-methylthiotetr-azole in volunteers and patients. Population-based clinical comparisons of antibiotics with and without this moiety[J]. Am J Surg, 1988, 155(5A): 40-44.
[5] LIANG H, MENG GY, ZHONG LQ, et al.Research progress of coagulation dysfunction induced by cefoperazone sodium and sulbactam sodium[J]. China Pharmaceuticals(中国药业), 2020, 29(1): 3.
[6] ZHU YC,LIANG L,SHEN J,et al.Clinical features and risk factors of coagulation disorders caused by cefoperazone sodium and sulbactam sodium[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2022, 57(9): 57.
[7] KIM JH, YOO SD, KIM DH, et al.Iliopsoas hematoma presenting with sudden knee extensor weakness: a case report[J]. Medicine (Baltimore), 2020, 99(50): e23497.
[8] UNDAS A, BRUMMEL K, MUSIAL J, et al.Blood coagulation at the site of microvascular injury: effects of low-dose aspirin[J]. Blood, 2001, 98(8): 2423-2431.
[9] WANG YY, ZHAI L.A case report of iliac muscle hematoma caused by low molecular weight heparin[J]. World Latest Medicine Information, 2021, 21(84): 288-290,293.
[10] MANSOR MFH, JUSOH AC, MOHD SM.Spontaneous iliopsoas hematoma in severe COVID-19 infection: a rising catastrophic complication[J]. Vis J Emerg Med, 2022, 27: 101308.
[11] VERGORI A, PIANURA E, LORENZINI P, et al.Spontaneous iliopsoas haematomas (IPHs): a warning for COVID-19 inpatients[J]. Ann Med, 2021, 53(1): 295-301.
[12] LI L,LI YF,WANG LP.Adverse event signal mining of low molecular weight heparin based on FAERS database[J]. Clinical Medication Journal(临床药物治疗学杂志), 2022(5): 43-49.
[13] BOUGET J, BALUSSON F, KERBRAT S, et al.Clinical use of low-dose parenteral anticoagulation, incidence of major bleeding and mortality: a multi-centre cohort study using the French national health data system[J]. Eur J Clin Pharmacol, 2022, 78(7): 1137-1144.
[14] FERNANDES C, PEREIRA P, RODRIGUES M. Spontaneous iliopsoas muscle haematoma as a complication of anticoagulation in acute cerebral venous thrombosis: to stop or not to stop (the anticoagulation)[J]. BMJ Case Rep, 2015, 6: bcr 2014206410.
[15] ARTZNER T, CLERE R, SCHENCK M, et al.Spontaneous iliopsoas hematomas complicating intensive care unit hospitalizations[J]. PLoS One, 2019, 14(2): e0211680.

药物诱发髂腰臀肌自发性出血1例分析

One case of spontaneous hemorrhage of iliopsoas and gluteal muscles induced by drugss

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.